You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

vemURAFenib

( VEM-ue-RAF-e-nib )
Funding:
Exceptional Access Program
  • vemURAFenib - For 1st line and 2nd line monotherapy treatment of BRAF V600 mutation-positive unresectable stage IIIC or IV melanoma or metastatic disease according to specific criteria.
  • vemURAFenib- For combination therapy (with cobimetinib) for the treatment of patients with previously untreated BRAF V600 mutation-positive unresectable stage Ill or stage IV melanoma
Other Name(s): Zelboraf ®
Appearance: tablet

You might also be interested in